Antibody Response To A Live-Modified Virus Vaccine Against Bovine Viral Diarrhoea In Dairy Cattle In A Field Trial

(1) Background: The objective of the study was to evaluate the long-term antibody response of dairy cows to a single dose of a commercial modified-live virus (MLV) vaccine against bovine viral diarrhea (Mucosiffa (R) CEVA Sante Animale, Liburne, France). (2) Methods: The study was carried out in a dairy cattle herd counting 290 animals negative for bovine viral diarrhoea virus (BVDV). The vaccination was implemented following the manufacturer's instructions. Twelve dairy cows were randomly selected before the study, and blood samples were collected right before the vaccination and then 12 times at 1-month intervals. The serum samples were screened using a virus neutralization test (VNT) and ELISA. (3) Results: Both tests showed that antibody titers increased significantly in all animals within the first month post-vaccination, and continued to increase significantly until the second (VNT) and third (ELISA) month post-vaccination. Antibody titers remained high and stable until the end of the study. Moreover, cows did not show any adverse reactions or clinical symptoms of the disease. (4) Conclusion: The results of this study indicated that the administration of one dose MLV vaccine was able to stimulate long-lasting (12-months) and strong antibody response in all vaccinated cows.